Research progress of nuclear-cytoplasmic translocation in the genesis and development of tumor

Abstract

Abstract: Nuclear-cytoplasmic translocation is an important cause of abnormal gene localization, which occurs at various stages of tumor development and is closely related to tumor treatment and drug resistance. In this paper, the basic structure, biological function and regulatory mechanism of nuclear translocation are described, and the role of nuclear-cytoplasmic translocation in the genesis and development of tumors, as well as the progress in tumor therapy and drug resistance are further reviewed, in order to provide theoretical basis for exploring novel anti-tumor strategies.

Key words: nuclear-cytoplasmic translocation, molecular mechanism, therapy, research progress

CLC Number:

R730.23

ZHOU Jie, HUANG Ying-hui. Research progress of nuclear-cytoplasmic translocation in the genesis and development of tumor[J]. Basic & Clinical Medicine, 2020, 40(8): 1119-1123.

References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018,68:7-30.
[2] Li FL, Liu JP, Bao RX, et al. Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis[J]. Nat Commun, 2018,9:508. doi:10.1038/s41467-018-02950-5.
[3] Lin DH, Correia AR, Cai SW, et al. Structural and functional analysis of mRNA export regulation by the nuclear pore complex[J]. Nat Commun, 2018,9:2319. doi:10.1038/s41467-018-04459-3.
[4 ] Bui KH, von Appen A, DiGuilio AL, et al. Integrated structural analysis of the human nuclear pore complex scaffold[J]. Cell, 2013,155:1233-1243.
[5] Zhou M, Liu H, Xu X, et al. Identification of nuclear localization signal that governs nuclear import of BRD7 and its essential roles in inhibiting cell cycle progression[J]. J Cell Biochem, 2006,98:920-930.
[6] Xu D, Grishin NV, Chook YM. NESdb: a database of NES-containing CRM1 cargoes[J]. Mol Biol Cell, 2012,23:3673-3676.
[7] Tavolieri MV, Droppelmann CA, Campos-Melo D,et al. A novel overlapping NLS/NES region within the PH domain of Rho guanine nucleotide exchange factor(RGNEF) regulates its nuclear-cytoplasmic localization[J]. Eur J Cell Biol, 2019, 98: 27-35.
[8] Chook YM, Blobel G. Karyopherins and nuclear import[J]. Curr Opin Struct Biol, 2001,11:703-715.
[9] Kapinos LE, Huang B, Rencurel C, et al. Karyopherins regulate nuclear pore complex barrier and transport function[J]. J Cell Biol, 2017,216:3609-3624.
[10] Barbato S, Kapinos LE, Rencurel C, et al. Karyopherin enrichment at the nuclear pore complex attenuates Ran permeability[J]. J Cell Sci, 2020,133.doi:10.1242/jcs.238121.
[11] Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism to intervention[J]. Nat Rev Cancer, 2004,4:106-117.
[12] Plafker K, Macara IG. Facilitated nucleocytoplasmic shuttling of the Ran binding protein RanBP1[J]. Mol Cell Biol, 2000,20:3510-3521.
[13] Gandhi UH, Senapedis W, Baloglu E, et al. Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma[J]. Clin Lymphoma Myeloma Leuk, 2018,18:335-345.
[14] Rahmani K, Dean DA. Leptomycin B alters the subcel-lular distribution of CRM1 (Exportin 1)[J]. Biochem Biophys Res Commun, 2017,488:253-258.
[15] Stelma T, Leaner VD. KPNB1-mediated nuclear import is required for motility and inflammatory transcription factor activity in cervical cancer cells[J]. Oncotarget, 2017,8:32833-32847.
[16] Cooper JP, Reynolds CP, Cho H, et al. Clinical development of fenretinide as an antineoplastic drug: pharm-acology perspectives[J]. Exp Biol Med (Maywood), 2017,242:1178-1184.
[17] Sorrentino G, Ruggeri N, Specchia V, et al. Metabolic control of YAP and TAZ by the mevalonate pathway[J]. Nat Cell Biol, 2014,16:357-366.
[18] Cyert MS. Regulation of nuclear localization during Signaling[J]. J Biol Chem, 276:20805-20808.
[19] de Polo A, Luo Z, Gerarduzzi C, et al. AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex[J]. J Mol Cell Biol, 2017,9:154-165.
[20] Liu H, Zhang H, Wu X, et al. Nuclear cGAS suppresses DNA repair and promotes tumorigenesis[J]. Nature, 2018,563:131-136.
[21] Kim J, McMillan E, Kim HS, et al. XPO1-dependent nuclear export is a druggable vulnerability in kras-mutant lung cancer[J]. Nature, 2016,538:114-117.
[22] Wang J, Lu Q, Cai J, et al. Nestin regulates cellular redox homeostasis in lung cancer through the keap1-nrf2 feedback loop[J]. Nat Commun, 2019,10:5043. doi:10.1038/s41467-019-12925-9.
[23] Lee PC, Fang YF, Yamaguchi H, et al. Targeting PKCδ as a therapeutic strategy against heterogeneous mechanisms of EGFR inhibitor resistance in EGFR-mutant lung cancer[J]. Cancer Cell, 2018,34:954-969.

[1]	GAN Zi-ying, TANG Hui. Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors [J]. Basic & Clinical Medicine, 2022, 42(4): 651-655.
[2]	HE Dan, RUAN Zhong-bao. Extracellular vesicles in the pathogenesis of atrial fibrillation [J]. Basic & Clinical Medicine, 2022, 42(4): 671-674.
[3]	ZHANG Shuang, LI Zhi-fan, QIAN Jie, WU Na-qiong. Effects of lipid-lowering therapy on coronary atherosclerotic plaque evaluated by intravascular imaging [J]. Basic & Clinical Medicine, 2022, 42(3): 366-371.
[4]	HE Xiao, HU Wei-jie, LYU Wen-chang, REN Yu-ping, WU Min, WU Yi-ping, ZHANG Qi. Advances on the roles of circular RNA in breast cancer [J]. Basic & Clinical Medicine, 2022, 42(3): 507-511.
[5]	JI Hui-fang, FU Yang, DONG Yi-fei. Advances in research on blood pressure regulation by clock gene PER [J]. Basic & Clinical Medicine, 2022, 42(2): 311-315.
[6]	BAI Jing, LIU Na, DING Li, LEI Li, NI Rui, YAN Shao-chun, SHAO Guo. Identification of differentially expressed genes in cervical carcinoma after radiotherapy [J]. Basic & Clinical Medicine, 2022, 42(2): 215-220.
[7]	GUO Xiao-peng, XING Bing, MA Wen-bin. Immune microenvironment and immunotherapy of pituitary adenomas [J]. Basic & Clinical Medicine, 2022, 42(1): 173-178.
[8]	WAN Bao, HUAN Fu-kui, ZHAO Yu, CHEN Huan, GENG Song-song, YAN Hui, ZHANG Yan-xin. Comparative analysis of supraclavicular area mobility in locally advanced esophageal cancer radiation therapy with two different fixed ways [J]. Basic & Clinical Medicine, 2022, 42(1): 131-135.
[9]	SONG Cong, WANG Da-yuan, SHEN Ming-wu, SHI Xiang-yang. Design and biomedical applications of core-shell tecto dendrimers [J]. Basic & Clinical Medicine, 2022, 42(1): 15-25.
[10]	LIU Jian. Progress of nucleic acid drugs and non-viral carriers in gene therapy [J]. Basic & Clinical Medicine, 2022, 42(1): 41-50.
[11]	. Research progress on molecular mechanism of the interaction between autophagy and apoptosis [J]. Basic & Clinical Medicine, 2021, 41(9): 1342-1346.
[12]	. A 79-year-old patient with advanced gastric cancer who received comprehensive therapy [J]. Basic & Clinical Medicine, 2021, 41(7): 1043-1046.
[13]	Hang-Hang WANG Dao-xin WANG. Research advances in NETs and acute respiratory distress syndrome [J]. Basic & Clinical Medicine, 2021, 41(7): 1047-1051.
[14]	. Research progress of mesenchymal stem cells in the treatment of pulmonary fibrosis [J]. Basic & Clinical Medicine, 2021, 41(7): 1056-1059.
[15]	GUO Xi, LAI Xin-xiu, YANG Mei-yan, LI Qiao-zhen, WANG Si-hang, SONG Zhang-yong. Research progress on novel molecules and new targets for the control of invasive fungi [J]. Basic & Clinical Medicine, 2021, 41(6): 904-908.